Search
Ospemifene
go.drugbank.com/drugs/DB04938ApprovedOspemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause … FDA approved on February 26, 2013.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesSynonyms: 2-(4-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol, 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanolIopydone
go.drugbank.com/drugs/DB20831ApprovedWithdrawnIopydone is a small molecule drug. Iopydone has a monoisotopic molecular weight of 346.83 Da.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 3,5-diiodo-4(1h)-pyridone1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea
go.drugbank.com/drugs/DB04336ExperimentalSynonyms: 1-(4-Amidinophenyl)-3-(4-Chlorophenyl)UreaN-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
go.drugbank.com/drugs/DB07734ExperimentalSynonyms: N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide4-Deoxy-4-Amino-Beta-D-Glucose
go.drugbank.com/drugs/DB03291ExperimentalSynonyms: 4-Deoxy-4-Amino-Beta-D-Glucose4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
go.drugbank.com/drugs/DB03307ExperimentalSynonyms: 4-[(6-Amino-4-Pyrimidinyl)Amino]BenzenesulfonamideLandiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigational[A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity … Landiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-(4-{(2S)-2-hydroxy-3-[{2-[(morpholin-4-ylcarbonyl)amino]ethyl}amino]propoxy}phenyl)propanoate, Benzenepropanoic acid, 4-[(2S)-2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl esterPindolol
go.drugbank.com/drugs/DB00960ApprovedInvestigationalPindolol is a first generation non-selective beta blocker used in the treatment of hypertension. … [A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsSynonyms: 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol, 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-olTizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalTizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. … Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons
Synonyms: 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazoleInternational brands: Sirdalud MROlmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalIn particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. … ARBs such as olmesartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression
Mixtures: OLMEDOXTAN A®, OLMETAN® A 40/5 TABLETAS RECUBIERTASCategories: Angiotensin 2 Receptor Blocker, Agents Acting on the Renin-Angiotensin System